Bupropion Hydrobromide

Extended-release formulation of the hydrobromide salt gives bupropion hydrobromide its distinct place among bupropion products, and it is indicated for major depressive disorder and seasonal affective disorder. The pharmacology is that of the parent compound: inhibition of dopamine and noradrenaline reuptake, without the serotonergic action that characterises the SSRI and SNRI classes. That mechanistic difference underlies the lower incidence of sexual adverse effects reported relative to serotonergic antidepressants. Formulating the active moiety as an extended-release tablet rather than an immediate-release one reflects the tolerability considerations that accompany this agent. The salt is a small molecule with formula C13H19BrClNO and a molecular weight of approximately 320.7 g/mol, and it is an approved agent that has completed the final phase of clinical development.

SMILES

Br.CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1

InChI

InChI=1S/C13H18ClNO.BrH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H